FemTech Leader Willow ® Adds Diverse Set Of Investors In Extended Series C Round

Willow, the company forever changing the way moms pump with the world’s first all-in-one, in-bra wearable breast pump with full spill-proof mobility, today announced an additional $26.8 Million in funding through a Series C Extension round –  led by Endeavour Vision, alongside NEA (New Enterprise Associates), Pura Vida Investments, Purple Arch Ventures (a part of Alumni Ventures Group), Logos Capital, and Gaingels.

This extension brings Willow’s total Series C investment to $81.8 Million.  With the most innovative breast pump on the market, Willow will use its latest growth capital funding to invest in new products and further expand its reach.

“We are excited to lead Willow’s Series C extension to further support the accelerated growth ahead for the company,” said Rob Barmann, Partner at Endeavour Vision. “As the innovation leader in its category, we believe that Willow will continue to develop groundbreaking innovations that disrupt the FemTech and MedTech industries.”

Recognizing that the functionality of breast pumps hadn’t changed in decades, Willow became a pioneer in the FemTech category by reinventing the breast pump. Willow’s proprietary, patented technology offers 100% spill-proof mobility for pumping moms, giving them freedom, dignity, and enabling joy in an otherwise stress-inducing aspect of motherhood.

“I’m excited about the growth we’ve been able to accomplish, and impact we’ve had, in such a short time, towards our mission of bringing joy to motherhood,” said Willow CEO, Laura Chambers. “With this additional funding, we will expand our international presence, grow brand awareness, and accelerate our innovative R&D pipeline of products that solve real problems for moms.”

Willow launched as a direct-to-consumer brand, bringing life-changing technology to women experiencing new motherhood.  Willow has since expanded to reach moms through retail and insurance channels, and was the fastest-growing brand in 2020 in retail for breastfeeding systems, according to NPD Group.  Its innovative breast pump has impacted more than 130,000 moms and counting.

SourceWillow®
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Bone Health Technologies Bone Health Technologies (BHT), a health technology innovator developing breakthrough non-invasive solutions for bone health, today announced the company has raised a...
Howard Robin, President and Chief Executive Officer of Nektar Therapeutics: "We are pleased to bring on TCGX as a new high-quality, long-term investor in Nektar as we advance rezpegaldesleukin through our Phase 2b studies in atopic dermatitis and alopecia areata. We are on track to report topline data from these studies in the first half of 2025, which will represent significant inflection points for Nektar. Today's financing further bolsters our financial position and extends the company's cash runway well into the third quarter of 2026."
MMI notes the funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.
“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.

By using this website you agree to accept Medical Device News Magazine Privacy Policy